Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 6
1982 9
1983 49
1984 95
1985 166
1986 217
1987 278
1988 328
1989 470
1990 769
1991 878
1992 998
1993 1185
1994 1282
1995 1475
1996 1407
1997 1494
1998 1534
1999 1519
2000 1510
2001 1612
2002 1653
2003 1722
2004 1737
2005 1498
2006 1236
2007 992
2008 959
2009 963
2010 986
2011 1026
2012 1022
2013 964
2014 954
2015 1012
2016 808
2017 795
2018 714
2019 644
2020 641
2021 639
2022 583
2023 487
2024 171

Text availability

Article attribute

Article type

Publication date

Search Results

37,236 results

Results by year

Filters applied: . Clear all
Page 1
BY-kinases: Protein tyrosine kinases like no other.
Hajredini F, Alphonse S, Ghose R. Hajredini F, et al. J Biol Chem. 2023 Jan;299(1):102737. doi: 10.1016/j.jbc.2022.102737. Epub 2022 Nov 22. J Biol Chem. 2023. PMID: 36423682 Free PMC article. Review.
ALK-positive lung cancer: a moving target.
Schneider JL, Lin JJ, Shaw AT. Schneider JL, et al. Nat Cancer. 2023 Mar;4(3):330-343. doi: 10.1038/s43018-023-00515-0. Epub 2023 Feb 16. Nat Cancer. 2023. PMID: 36797503 Free PMC article. Review.
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
Pan Y, Han H, Hu H, Wang H, Song Y, Hao Y, Tong X, Patel AS, Misirlioglu S, Tang S, Huang HY, Geng K, Chen T, Karatza A, Sherman F, Labbe KE, Yang F, Chafitz A, Peng C, Guo C, Moreira AL, Velcheti V, Lau SCM, Sui P, Chen H, Diehl JA, Rustgi AK, Bass AJ, Poirier JT, Zhang X, Ji H, Zhang H, Wong KK. Pan Y, et al. Cancer Cell. 2023 Jan 9;41(1):88-105.e8. doi: 10.1016/j.ccell.2022.11.015. Epub 2022 Dec 15. Cancer Cell. 2023. PMID: 36525973 Free PMC article.
Rare molecular subtypes of lung cancer.
Harada G, Yang SR, Cocco E, Drilon A. Harada G, et al. Nat Rev Clin Oncol. 2023 Apr;20(4):229-249. doi: 10.1038/s41571-023-00733-6. Epub 2023 Feb 20. Nat Rev Clin Oncol. 2023. PMID: 36806787 Free PMC article. Review.
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia.
Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M, Hogg SJ, Bewersdorf JP, Han C, Singer ME, Cui D, Erickson CE, Tittley SM, Penson AV, Knorr K, Stanley RF, Rahman J, Krishnamoorthy G, Fagin JA, Creger E, McMillan E, Mak CC, Jarvis M, Bossard C, Beaupre DM, Bradley RK, Abdel-Wahab O. Wang E, et al. Cancer Cell. 2023 Jan 9;41(1):164-180.e8. doi: 10.1016/j.ccell.2022.12.002. Epub 2022 Dec 22. Cancer Cell. 2023. PMID: 36563682 Free PMC article.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma.
Lee JY, Jonus HC, Sadanand A, Branella GM, Maximov V, Suttapitugsakul S, Schniederjan MJ, Shim J, Ho A, Parwani KK, Fedanov A, Pilgrim AA, Silva JA, Schnepp RW, Doering CB, Wu R, Spencer HT, Goldsmith KC. Lee JY, et al. Cell Rep Med. 2023 Jun 20;4(6):101091. doi: 10.1016/j.xcrm.2023.101091. Cell Rep Med. 2023. PMID: 37343516 Free PMC article.
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Drilon A, Sharma MR, Johnson ML, Yap TA, Gadgeel S, Nepert D, Feng G, Reddy MB, Harney AS, Elsayed M, Cook AW, Wong CE, Hinklin RJ, Jiang Y, Brown EN, Neitzel NA, Laird ER, Wu WI, Singh A, Wei P, Ching KA, Gaudino JJ, Lee PA, Hartley DP, Rothenberg SM. Drilon A, et al. Cancer Discov. 2023 Aug 4;13(8):1789-1801. doi: 10.1158/2159-8290.CD-23-0361. Cancer Discov. 2023. PMID: 37269335 Free PMC article.
37,236 results
You have reached the last available page of results. Please see the User Guide for more information.